Nexstim: The end of the year laid a firmer foundation for the future
The key figures were already known based on preliminary data from the beginning of the year, which were now revised. Revenue was slightly higher than the preliminary data suggested and the result hit our forecasts. The H2 cash flow was also at the expected zero level considering the partial transfer of cash flow to 2024 through increased trade receivables. The report did not contain any surprises, so forecast changes were small. Nexstim expects increasing revenue and earnings, which disperses concerns related to cash flow adequacy. We expect the company to continue on the path of profitable growth, although the cashflow is likely to remain negative this year.
Nexstim
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read more on company pageKey Estimate Figures03.01
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 9.5 | 7.0 | 8.8 |
growth-% | 48.91 % | -26.56 % | 25.72 % |
EBIT (adj.) | 0.8 | -1.1 | -0.4 |
EBIT-% (adj.) | 8.79 % | -15.65 % | -4.79 % |
EPS (adj.) | 0.18 | -0.17 | -0.07 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | 22.85 | - | - |
EV/EBITDA | 22.00 | - | 306.75 |